Top 5 Best Performing Healthcare Mutual Funds Year to Date - Best Performing Funds Year To Date
25 January 2013 - 4:39AM
Zacks
Investors seeking long-term aggressive holdings need not look
beyond mutual funds betting on the technology sector. Even though
such funds experience relatively higher levels of volatility, they
tend to outperform other categories when markets as a whole are
seeing an uptrend. Recent results from tech firms have also shown
that the sector is gearing up to enter a new era of success and
prosperity. Further, fund prices are based on stronger fundamentals
compared to their initial boom period, substantially reducing the
risk involved.
Below we will share with you the 5 best performing healthcare
mutual funds year to date. To view the Zacks Rank and past
performance of all healthcare funds, then click here.
Mutual Fund
|
Zacks Rank
|
Total Return YTD
|
ProFunds Biotech Ultra Sector
|
#1 Strong Buy
|
64.18%
|
Fidelity Select Biotechnology
|
#2 Buy
|
36.59%
|
Rydex Biotechnology
|
#4 Sell
|
36.54%
|
T. Rowe Price Health Sciences
|
#4 Sell
|
31.93%
|
VALIC Company I Health Sciences
|
#4 Sell
|
31.71%
|
ProFunds Biotechnology UltraSector (BIPSX) invests in
equity securities and derivatives that in the opinion of the fund
advisors possess daily return characteristics identical to one and
a half times the daily return of the Dow Jones U.S. Biotechnology
Index. The healthcare mutual fund is non-diversified and has a
three year annualized return of 22.93%.
The healthcare mutual fund has a minimum initial investment of
$15,000 and an expense ratio of 2.73% compared to a category
average of 1.52%.
Fidelity Select Biotechnology (FBIOX) seeks capital
growth. The fund invests the majority of its assets in
biotechnology companies as well as those seeking to benefit from
advances in the biotechnological sector. It focuses on acquiring
common stocks and may also purchases securities issued by foreign
companies. The healthcare mutual fund has a three year annualized
return of 21.61%.
Rajiv Kaul is the fund manager and has managed this healthcare
mutual fund since 2005.
Rydex Biotechnology (RYOIX) utilises a large share of its
assets to purchase equity securities and derivatives issued by
domestic biotechnology companies. It focuses on acquiring
securities of small and mid-cap companies. The healthcare mutual
fund has a three year annualized return of 18.92%.
As of December 2012, this healthcare mutual fund held 46 issues,
with 8.75% of its total assets invested in Amgen Inc.
T. Rowe Price Health Sciences (PRHSX) seeks capital
growth over the long term. The fund invests heavily in common
stocks of companies whose primary operations are related to
healthcare products medicine or life sciences. The fund focuses on
investing in large and mid-cap firms but may also purchase stock of
smaller companies. The healthcare mutual fund has a three year
annualized return of 19.43%.
The healthcare mutual fund has a minimum initial investment of
$2,500 and an expense ratio of 0.82% compared to a category average
of 1.52%.
VALIC Company I Health Sciences (VCHSX) invests the
majority of its assets in common stocks of healthcare products,
medicine or life sciences related companies. It focuses mainly on
investing in large and mid-cap companies. Not more than 35% of its
assets may be invested foreign securities. The healthcare mutual
fund has a three year annualized return of 18.99%.
Kris H. Jenner is the fund manager and has managed this
healthcare mutual fund since 2000.
To view the Zacks Rank and past performance of all healthcare
mutual funds, then click here.
About Zacks Mutual Fund Rank
By applying the Zacks Rank to mutual funds, investors can find
funds that not only outpaced the market in the past but are also
expected to outperform going forward. Learn more about the Zacks
Mutual Fund Rank.
(BIPSX): ETF Research Reports
(FBIOX): ETF Research Reports
(PRHSX): ETF Research Reports
(RYOIX): ETF Research Reports
(VCHSX): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research